We held an international consensus conference on frontotemporal dementia, behavioral disturbances, and parkinsonism linked to chromosome 17 to determine whether these are homogeneous or heterogeneous disorders, to agree on terminology, and to develop strategies for further research. The group identified 13 kindreds with sufficient evidence for linkage, finding in common to all a critical 2 CM between markers D17S791 and D17S800. There was agreement that (I) despite previous descriptions that have emphasized one or another clinical or neuropathological feature, the kindreds share clinical and neuropathological features; (2) until more specific information about the genetic defects becomes available, this disorder is best termed frontotemporal dementia and parkinsonism linked to chromosome 17; and (3) hrther research will be enhanced by identifying the gene or genes responsible for this disorder, detecting additional cases within known families and, in new families, correlating mutations with phenotypes and more fully delineating the clinical, neuropsychological, and neuropathological characteristics of this disorder. to describe such cases varies and many names have been used. Nonspecific dementia is the most commonly used term, but dementia lacking distinctive histology, Pick's disease without Pick bodies, and frontotemporal dementia [2-61 are terms that have also been used. These dementias have been difficult to study because the clinical variability makes it unclear whether they represent a distinct clinical syndrome. Many patients later found to have one of these dementias were erroneously thought to have AD, but in some cases atypical features were recognized [7, 81. Many patients with nonspecific neuropathology or frontotemporal dementia have a disease that is hereditary, up to 60% in one series [ l , 31, 9, lo]. Recently, dementia in 1 such family was linked to chromosome From the
used. These dementias have been difficult to study because the clinical variability makes it unclear whether they represent a distinct clinical syndrome. Many patients later found to have one of these dementias were erroneously thought to have AD, but in some cases atypical features were recognized [7, 81. Many patients with nonspecific neuropathology or frontotemporal dementia have a disease that is hereditary, up to 60% in one series [ l , 31, 9, lo] . Recently, dementia in 1 such family was linked to chromosome T o extend our knowledge about chromosome 17-linked dementia, a forum was needed to bring together investigators who could compare the clinical and neuropathological features of the disorders in identified kindreds, determine whether they share common elements, develop a consensus about these issues, and formulate strategies for further research.
Methods
An international consensus conference was held in Ann Arbor, Michigan, October 4 through 6, 1996. Before the meeting, the organizing committee searched the medical literature to identify all known kindreds with a neurodegenerative disease linked to chromosome 17. We contacted investigators who were familiar with each kindred and invited them to attend the meeting and to present clinical, genetic, and neuropathological data. They were also asked to identify any other kindreds that have been linked to chromosome 17. We gave the investigators a list of publications related to their kindreds that they checked for accuracy and completeness. We distributed a list of key published references to all participants for review before the meeting. The conference included clinicians, geneticists, and neuropathologists associated with each kindred and an independent panel of senior commentators with expertise in dementia and neurodegenerative disorders. These commentators provided perspective and a summary of each day's deliberations.
At the beginning of the meeting, the organizing committee instructed participants on procedures for achieving consensus, and the moderators used previously described methods to encourage consensus among all participants [l2] . In a plenary session on the first day, the invited participants presented the clinical, laboratory, neuropathological, and genetic features of each kindred showing linkage to chromosome 17 and cases of sporadic and familial neurodegenerative disorders that clinically and neuropathologically resemble the described kindreds but are not known to be linked to chromosome 17. O n the second day, clinicians, neuropathologists, and geneticists held three discipline-specific sessions to present and discuss in detail the characteristics of the kindreds and to address a list of predetermined questions. In a final plenary session on the third day, the conclusions of the discipline-specific sessions were presented and discussed and the participants agreed on a final consensus statement.
The conference-organizing committee provided a draft consensus statement in advance of the meeting to guide the discussions. The participants reviewed the statement and modified both the statement and the tables summarizing information presented at the meeting. Members of the organizing committee served as moderators of the disciplinespecific sessions and recorded the results of the consensus.
Results

Kindreds with Frontotemporal Dementia and Parkinsonism Linked to Chromosome I 7
The participants discussed 25 families they had identified. They agreed that 8 families have disease that is definitely linked to the critical region of chromosome 17 because of multipoint affected-only LOD scores greater than 3, and they classified 5 families as having disease that is probably linked because of LOD scores between 1 and 3 (Table I ). The remaining 12 kindreds had similar clinical and neuropathological features but had only a small number of available tissue samples for DNA testing. In these kindreds where LOD scores were less than 1, there was no indication of a genetic mutation at another location, but linkage to chromosome 17 had to be classified as uncertain. Information about these kindreds was tabulated, but they were otherwise not considered further in the deliberations.
The 13 families with definitely and probably linked disease have been analyzed by a subset of markers that and cognitive decline predominate. The motor abnormalities consist principally of parkinsonian extrapyramidal disorders with bradykinesia, rigidity, and postural instability, but without resting tremor. Corticospinal disturbances, muscle wasting, and fasciculations are seen in a minority of the cases. No significant benefit was observed with levodopa when it was tried. Supranuclear ophthalmoplegia and apraxia of eyelid opening is sometimes observed. Autonomic function is spared, at least early, and incontinence of both bladder and bowel occurs late in the course as dementia becomes increasingly severe. Changes in body weight may Affected individuals in families with probable linkage are similar to those in families with definite linkage to chromosome 17. We were unable to identify any features that reliably distinguish linked families from families known not to be linked to chromosome 17 or a family with a clinically and neuropathologically similar disorder linked to chromosome 3 [ 141.
Neuropathological Features in Kindreds with Disease Linked to Chromosome 1 7
Frontotemporal atrophy is a consistent feature, and basal ganglia atrophy and substantia nigra depigmentation are found in most kindreds (Table 3 ) . Hemispheric atrophy is asymmetric in only 3 families with disease of probable linkage to chromosome 17.
Microscopic examination consistently reveals neuronal loss, neuropil vacuolation of the superficial layers of the cerebral cortex, and gliosis in both gray and white matter of variable intensity (Table 4 ). In 4 kindreds (Irish family 1, pallido-ponto-nigral degeneration, familial multiple system 7-opathy, and familial progres- family 2, the Australian family, I h t c h family I, and Dutch family 11) show ballooned neurons without associated 7 pathology, and the remaining 4 kindreds lack both abnormalities. These features can be used to subdivide the kindreds into the following 4 groups: T and ballooned neuron positive; 7-positive alone; ballooned neuron positive alone; and ballooned neuron negative. Because varying techniques have been used in evaluating T pathology, this classification is only tentative. At present, it is the substantial similarities rather than these histological distinctions between kindreds that remain most remarkable. Semiquantitative regional histopathological examination reveals neuronal loss and gliosis that is most severe in the frontal and temporal cortices, accompanied by neuronal loss and gliosis in the substantia nigra (Table   5 ). In most cases, neurons of the hippocampal formation are preserved. Neuronal loss with degenerative changes is moderate in the basal ganglia. Neuronal loss and gliosis of the amygdala is severe, except in 3 kin- No differences are found between families with definitely linked and probably linked disease, in the distribution or severity of cortical neuronal loss and gliosis, basal ganglia pathology, or severity of depigmentation and neuronal loss in the substantia nigra. Argyrophilic and .r-positive inclusions are not found in any cases of the families with disease of probable linkage. Diffuse Lewy bodies, amyloid deposition, and Pick bodies exceeding those expected for age are not found in any of the families with definitely or probably linked disease. Neuritic plaques excessive in number for age are seen only in rare cases.
Discussion
The highest priority in advancing knowledge of chromosome 17-linked neurodegenerative disease is to characterize the gene or genes responsible. Identification of a gene is inevitable, but the search may be protracted. Progress in our understanding will be aided by collaboration to share genetic information, identify additional kindreds, and characterize more fully the clinical, neuropsychological, and neuropathological features of this disease.
Classift'cation of Kindreds
Clear commonalities emerged in discussions of the clinical and neuropathological features of the kindreds with disease linked to chromosome 17q21-22. The predominant features included a severe behavioral disorder characteristic of the frontotemporal dementia accompanied by a parhnsonian syndrome without resting tremor. Neuropathologically, the common features consisted of neuronal loss, gliosis, and spongiosis most severe in the frontal, temporal, and cingulate cortices, and neuronal loss in substantia nigra. Until the genetics of these kindreds is fully defined, it appears reasonable to consider them together.
Several sporadic disorders have frontotemporal dementia and parkinsonism similar to that seen in chromosome 17-linked kindreds. The sporadic cases we considered were those in which no other relatives appeared to be similarly affected after a careful review of their medical history and considering their age at the time of death. The relationship of the sporadic disorders to the hereditary disorders is unknown. Although there are similarities, none of the names applied to these sporadic disorders adequately describes all of the linked hereditary cases. Likewise, none of the names used to describe a single hndred is sufficiently inclusive or descriptive to be applied to all. We therefore agreed to a new nomenclature. Because the dominant features of the hereditary disorder consist of a frontotemporal dementia with parkinsonism, we adopted the term fiontotemporal dementia undparkinsonism linked to chromosome 17 (FTDP-17). features have received comment. The frequency of clinical features also varies considerably during the illness, and longitudinal clinical observations are needed that note disease severity. Collaborations are encouraged for standardization of clinical data and performance of clinical studies presently available at only a few sites. A systematic review of available structural imaging studies would provide information about the utility of computed tomographic scanning and magnetic resonance imaging in recognizing the focal atrophic change uniformly identified by gross inspection at postmortem examination. In particular, neuropsychometric testing, standardized neuropsychiatric assessment, and functional brain imaging offer the possibility of distinguishing, before death, individuals with this disorder from those with familial AD. EEG findings appear unlikely to be sufficiently specific to aid in recognition of FTDP-17. Neuropathological findings suggest that measurement of cerebrospinal fluid 'r levels may be informative, but this has not yet been studied in these kindreds. There is no evidence thai-apolipoprotein E genotype alters the expression of these disorders.
Need f i r Additional Clinical Studies
Need f i r Additional Neuropathologicc;rl Studies
The distinctive combination and disi:ribution of neuropathological findings identified in kindreds with disease linked to chromosome 17 will assist in the identification of suspected cases from available autopsy cases. The following four issues concerning the neuropathology of FTPD-17 emerged and should be evaluated further: (1) characterization of the abnormal T protein to detect similarities between kindreds in which it was found; (2) evaluation of abnormalities in density and distribution of cortical synapses by using immunocytochemical and morphometric techniques; (3) determination of the laminar distribution of cortical pathology within affected regions; and (4) development of a protocol for consistent and appropriate handling of brains harvested from frontotemporal dementia cases, including sections, stains, and immunocytochemistry. T o permit comparability between cases, sections from the following regions should be evahated with hematoxylin and eosin stain, Bielschowsky stain, and T protein immunocytochemistry: frontal cortex; temporal cortex; anterior cingulate gyrus; caudate nucleus, putamen, globus pallidus; amygdaloid nucleus; thalamus; hippocampus; midbrain with substantia nigra; pons; and cerebellar vermis and medulla. Collaborations are encouraged to assess the frequency and range of severity of neuropathological features in specific brain regions and their relationship to clinical symptoms.
Need for Additional Genetic Studies
The families with FTDP-17 conceivably could be distantly related to each other or to as yet unidentified families. This possibility can be assessed by searching for shared haplotypes that will provide clues to the more precise location of the susceptibility gene. A series of microsatellite polymorphisms that are recommended for haplotype comparison have been identified in the critical region between D17S791 and D17S800. Two Centre d'Etudes du Polymorphisme Humain (CEPH) reference subjects were agreed on for standardization of allele assignments (http://www.cephb.fr/cephgenethon-maphtml). (Haplotypes and information concerning the markers and reference subjects chosen are posted on the World Wide Web, and the Internet address can be obtained from the authors. Haplotypes will be accepted from the scientific community and distributed anonymously using the web site.)
Identzjcation of Additional Cases
It is important to find additional families with FTDP-17 and to identify new members of the existing families. Carefully assessed subjects with sporadic diseases similar to FTDP-17 may be helpful in screening candidate genes for mutations. Without additional subjects, we are unlikely to define further the disease susceptibility locus on 17q21-22. At present, the closest recombinants that define the region containing the disease susceptibility locus are 2 cM apart. Additional kin- Families with 2 or more affected individuals (the proband and 1 or more first-or second-degree relatives) can provide information that will assist in furthering the localization of the disease gene. The family history should be explored carefully in any patient with a clinical or neuropathological profile similar to that described for FTDP-17, by questioning the affected individual, those who accompany the patient to the clinical examination, and several first-and second-degree relatives they identify. Consultation with a geneticist or genetic counselor can be helpful in thoroughly exploring the family history. Clinicians caring for affected subjects should be cautious when interpreting genetic research data in discussions with these subjects and their families. Until the complete implications of inheriting specific mutations are known, only limited genetic counseling can be provided.
Heterogeneity in FTDP-17
Although kindreds showed many clinical and neuropathological features in common, noteworthy differences emerged. Asymmetric cerebral atrophy was found in 2 lundreds with prominent aphasia, although this and other speech/language disorders were prominent in many families. Further study of known affected individuals and identification of additional families will provide a more complete understanding of the clinical and neuropathological heterogeneity in FTDP-17. The available genetics data suggest that mutations of one or possibly a few genes on chromosome 17q21-22 account for FTDP-17. The following two genetic mechanisms could explain the heterogeneity in FTDP-17 kindreds: (I) allelic mutations in the same genes (allelic heterogeneity), and (2) mutations in different genes located on chromosome 17q2 1-22 (locus heterogeneity). Many of the affected families are large and geographically dispersed, and thus are likely to be influenced by heterogeneity of genetic background and diverse environmental exposures. Hence, it is unlikely that genetic background or environmental factors contribute importantly to the phenotypic differences between families. This notion is reinforced because the high penetrance of the clinical and neuropathological phenotypes appear to cosegregate. We make these inferences cautiously because recent work with other disorders such as Machado-Joseph disease suggests that substantial clinical heterogeneity can occur within families with the same mutations [17] .
Prevalence of FTDP-17
Inadequate information exists to determine the prevalence of FTDP-17; however, the number of identified kindreds is increasing rapidly as this condition is becoming more widely known. The number of families identified has doubled since planning for this conference began in October 1995. Identification of one or more genetic mutations will permit testing of individuals, which will help to determine the prevalence of 
Clues to the Pathogenesis of FTDP-17
Both T accumulation and ballooned neurons are common to several sporadic dementing disorders. Accumulation of T protein may be important in the pathogen- 
